Compare PCRX & CCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | CCO |
|---|---|---|
| Founded | 2006 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2010 | 2005 |
| Metric | PCRX | CCO |
|---|---|---|
| Price | $22.83 | $2.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 6 |
| Target Price | ★ $35.33 | $2.21 |
| AVG Volume (30 Days) | 736.7K | ★ 10.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 107.44 | ★ 110.81 |
| EPS | ★ 0.16 | 0.04 |
| Revenue | $541,533,000.00 | ★ $1,604,140,000.00 |
| Revenue This Year | $9.77 | $5.23 |
| Revenue Next Year | $9.71 | $3.20 |
| P/E Ratio | $140.38 | ★ $59.38 |
| Revenue Growth | ★ 26.04 | 6.57 |
| 52 Week Low | $18.80 | $0.81 |
| 52 Week High | $27.99 | $2.43 |
| Indicator | PCRX | CCO |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 56.69 |
| Support Level | $20.41 | $1.96 |
| Resistance Level | $23.82 | $2.41 |
| Average True Range (ATR) | 1.01 | 0.02 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 68.81 | 7.14 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.